SIRPα combination therapy with CPI (ezabenlimab, pembrolizumab) yielded a study-level ORR of 18.8% to 20.0% in colorectal, endometrial, and head and neck cancer patients. This evidence concerns the gene SIRPA and head and neck cancer.